Urologix, Inc. reported unaudited earnings results for the second quarter and six months ended December 31, 2013. For the quarter, the company reported operating loss of USD 892,000, loss before income taxes of USD 1,069,000 and net loss of USD 1,085,000 or USD 0.05 basic and diluted loss per share on sales of USD 3,806,000 against operating loss of USD 829,000, loss before income taxes of USD 954,000 and net loss of USD 970,000 or USD 0.05 basic and diluted loss per share on sales of USD 4,354,000 for the same period a year ago. The revenue decline compared to the second quarter of fiscal year 2013 was due to lower volume of units sold in both product lines. The change in net loss in the second quarter of fiscal year 2014 was primarily due to lower sales and gross profit compared to the prior year second quarter.

For the six months, the company reported operating loss of USD 2,055,000, loss before income taxes of USD 2,391,000 and net loss of USD 2,419,000 or USD 0.11 basic and diluted loss per share on sales of USD 7,585,000 against operating loss of USD 1,756,000, loss before income taxes of USD 2,008,000 and net loss of USD 2,040,000 or USD 0.10 basic and diluted loss per share on sales of USD 8,324,000 for the same period a year ago. Net cash used for operating activities was USD 990,000 and purchase of property and equipment was USD 27,000 against net cash used for operating activities of USD 786,000 and purchase of property and equipment was USD 36,000 for the same period a year ago.